-+ 0.00%
-+ 0.00%
-+ 0.00%
Brandenburg Kapital portfolio firm 4TEEN4 wins FDA fast-track status for cardiogenic shock drug Invobenitug
Share
Listen to the news
Brandenburg Kapital portfolio firm 4TEEN4 wins FDA fast-track status for cardiogenic shock drug Invobenitug
  • Brandenburg Kapital portfolio company 4TEEN4 Pharmaceuticals secured U.S. FDA Fast Track designation for Invobenitug in cardiogenic shock.
  • Invobenitug is in a Phase Ib/IIa trial across several European countries.
  • Brandenburg Kapital has held an investment stake in 4TEEN4 since 2019.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brandenburg Kapital GmbH published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending